D-cycloserine Augmented CBT for Panic Disorder

• Status: Terminated
• Trial end date: 2018-04-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether d-cycloserine augments the clinical effects of exposure-based cognitive-behaviour therapy for panic disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oxford
• Collaborator: Medical Research Council
• Treatments: Cycloserine

Criteria

Inclusion Criteria:

• clinical diagnosis of panic disorder

• at least moderate agoraphobic avoidance

Exclusion Criteria:

• psychoactive medication last 6 weeks

• exposure-based cognitive-behaviour treatment for panic disorder and agoraphobia during last 3 months

• female participant who is pregnant or breast-feeding

• lifetime history of psychosis, bipolar disorder, alcohol, medication or drug abuse or dependence; current primary depressive disorder

• lifetime history of epilepsy or other significant disease or disorder